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 Age-related macular degeneration (AMD) is the leading
cause of irreversible blindness among people who are 50 years
of age or older in the developed world [1,2]. The choroidal
neovascularization (CNV) accounts for the severely progres-
sive decrease of central visual acuity among 90% of
neovascular/exudative (wet) AMD [3]. Although the etiologi-
cal factors and pathology process of CNV still remain elusive,
vascular endothelial growth factor (VEGF)-A is a major regu-
lator of angiogenesis and vascular permeability implicated in
the development of the CNV involving pathological angio-
genesis and increased vascular permeability [4,5]. Multiple
biologically active forms of VEGF-A are generated by alter-
native mRNA splicing and proteolytic cleavage, and two
isoforms have been detected in choroidal neovascular lesions
[6].
Although conventional laser photocoagulation [7] and
photodynamic therapy (PDT) [8] were applied as prevalent
therapeutic modalities for CNV, a small percentage of patients
with CNV fit the conventional laser and usually the visual
outcome was poor after the treatment. Furthermore, over half
of the treated patients with CNV have a recurrence after laser
[9]. Verteporfin PDT (Visudyne; Novartis, East Hanover, NJ)
has been shown to stabilize or slow down vision loss in pa-
tients with neovascular AMD but requires repeated treatments
which may be associated with cumulative damage to normal
retinal structures [10]. Neither of these options are effective
for all patients with neovascular AMD, and improved or even
stabilized visual acuity (VA) is not commonly achieved even
with treatment. Recently, the therapies that aimed at VEGF-A
as the target for the management of CNV associated with AMD
have demonstrated encouraging signs of biologic activity with
confirmed efficacy and safety such as the intravitreal injec-
tion of Pegaptanib [11] and Ranibizumab [12]. But the half-
life of them is less than four days after nonclinical vitreous
administration, repeated intravitreal injections were needed,
©2008 Molecular Vision
Recombinant anti-vascular endothelial growth factor fusion
protein efficiently suppresses choridal neovasularization in
monkeys
Ming Zhang,1 Junjun Zhang,1 Mi Yan,1 Hong Li,2 Chun Yang,2 Dechao Yu2
1Department of Ophthalmology, West China Hospital, Sichuan University, China; 2Chengdu Kanghong Biotechnology Co. Ltd,
Sichuan Province, China
Purpose: KH902 is a fusion protein which combines ligand binding elements taken from the extracellular domains of
vascular endothelial growth factor (VEGF) receptors 1 and 2 and the Fc portion of IgG1. This study is designed to
examine the inhibitory effect of KH902 in the choroidal neovascularization (CNV) monkey model.
Methods: The binding affinity with VEGF was measured by using the human VEGF ELISA kit, and the biological
activity effect of KH902 was assayed by an in vitro inhibition experiment on human umbilical vein endothelial cell
proliferation that was induced by VEGF. The experimental CNV was induced by causing perimacular laser injury in the
eyes of rhesus monkeys and confirmed by fluorescence fundus angiography (FFA), optical coherence tomography (OCT),
and multifocal electroretinograms (mf-ERG) 20 days after the infliction of the laser injury. KH902 was delivered to the
animals through intravitreal injection at various doses. Monkeys were observed four weeks after injection by ophthalmic
examination, FFA, OCT, mf-ERG, histopathology, and immunohistochemistry analysis.
Results: KH902 binds VEGF at a high affinity with a mean of IC50 of 10 pM. KH902 at 41 nM can completely block
VEGF-induced cell proliferation and KH902 at 10.7 nM can block 82.6% of cell growth. In the eyes of the treatment
group, which received 300 µg and 500 µg KH902, choroidal neovascularization leakage was obviously less than before
injection, and no leakage was observed at the end of the observation after injection. No high reflect light echogenic mass
was detected by OCT. However, in the 0.1 mg KH902-treated and control eyes, the leakage and high reflect light echogenic
mass still existed. The reduction of experimental CNV was greater in eyes treated with 300 µg and 500 µg KH902 than in
eyes treated with 0.1 mg KH902 and the control eyes. There were fiber-vasculosa membrane proliferation in the 100 µg
KH902-treated eyes and control eyes but not in the 300 µg and 500 µg KH902-treated eyes under histopathologic obser-
vation. The results of mf-ERG demonstrated that there was greater improvement in the 300 µg and 500 µg KH902-treated
eyes than in the 100 µg KH902-treated eyes and control eyes.
Conclusions: KH902 presents high affinity with VEGF and inhibitory activity on the proliferation of human umbilical
vein endothelial cells (HUVECs) induced by VEGF. A single 300 µg or 500 µg KH902 intravitreal injection effectively
inhibited leakage and growth of the CNV in rhesus monkeys without evidence of toxicity. This study suggests that KH902
has promise as a local antiangiogenic treatment of CNV.
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37which increased the risks of endophthalmitis and retina de-
tachment [12].
KH902 is a humanized fusion protein, which is aimed to
bind to all forms of VEGF-A. It can efficiently bind VEGF
and can theoretically inhibit proliferation of endothelial cells.
The present study was designed to demonstrate the binding
affinity with VEGF and efficacy of KH902 in the suppression
of the experimental CNV in the rhesus monkey.
METHODS
 KH902 is an engineered protein which contains the extracel-
lular domain 2 of vascular endothelial growth factor receptor
(VEGFR) 1 (Flt-1) and extracellular domain 3,4 of VEGFR2
(KDR-3,4) fused to the Fc portion of human immunoglobulin
G1. The molecular weight is about 143 kDa.
Vascular endothelial growth factor receptor binding as-
say of KH902 and human umbilical vein endothelial cell pro-
liferation assay:  Binding affinity with VEGF was measured
by using the human VEGF ELISA kit (DY293B; R&D, Min-
neapolis, MN) for detecting free human VEGF in mixtures of
KH902 (concentration ranging from 0.1 pM to 0.5 nM) with
human VEGF. And the affinity was evaluated by IC50. IC50
was calculated by the corresponding concentration of KH902
with half of free VEGF. To determine the binding affinity of
KH902 with VEGF, binding assays were performed in which
different concentrations of KH902 were incubated with
VEGF165 and the method was in accordance with the ELISA
kit.
To evaluate the bioactivity of KH902 in vitro, the prolif-
eration of human umbilical vein endothelial cells (HUVECs)
was taken as a good index. HUVECs were cultured in condi-
tioned medium containing 0.2 nM VEGF and serial concen-
trations of KH902 (41 nM, 10.7 nM, and 0 nM). The control
group was medium without VEGF and KH902. Four days later,
15 µl CCK-8 (Dojindo Molecular Technologies,Kumamoto,
Japan) was added into each well and the absorbance was mea-
sured at 570/630 nm after 2 h.
Animals and laser-induced choroidal neovascularization:
Rhesus monkeys were used in accordance with the Associa-
tion for Research in Vision and Ophthalmology (ARVO,
Rockville, MD) resolution on use of animals in research and
in compliance with guidelines developed by the Animal Care
Committee of the Sichuan University (Chengdu, China). Mon-
keys weighed between 2 and 5 kg, and ages ranged from three
to six years. For the experimental procedures, animals were
anesthetized with 2.5% soluble pentobarbitone (1 ml/kg).
Supplemental anesthesia was given with 2.5% soluble pento-
barbitone (0.8 ml/kg). Topical ocular anesthesia was obtained
with proparacaine.
CNV was induced by a laser (Vissulus 532s Laser Photo-
coagulator, Carl Zeiss Meditec AG, Jena, Germany). Laser
photocoagulations were conducted to the perimacular region
of monkey eyes. Lesions were placed in the macula with eight
spots. Laser lesions were placed in a circular fashion around
the macula about one disk diameter from the foveal center.
Care was taken to avoid lasering the fovea. The approximate
laser parameters were as following: spot size, 50 µm; laser
power, 300-500 mW; and exposure time, 0.05 s. Color photo-
graphs were taken on the day of the laser procedure. The ulti-
mate laser power used was determined by the appearance of a
small blister and the sound of a pop indicating a puncture of
Bruch’s membrane. If no blister or pop was noted, a second
laser spot was placed over the initial spot.
Intravitreal injection of KH902 and control:  Twenty days
after the laser burn, monkeys were divided into two groups,
the KH902 treatment group and the control group, according
to the results of fluorescence fundus angiography (FFA) and
optical coherence tomography (OCT). The eyes of the treat-
ment group received three doses of KH902 (500 µg, 300 µg,
and 100 µg) and the control group received an intravitreal
vehicle injection. Before the intravitreal injection, eyes of the
monkeys were administrated tobramycin drops in the fornices
over eight times. After the animal was anesthetized, the eye
was anesthetized with a drop of proparacaine in the conjuncti-
val sac and the pupil was dilated by 0.5% tropicamide eye
drops (Mydrin P; Santen Pharmaceutical, Osaka, Japan). A
5% povidone iodine solution was placed in the conjunctival
sac. A self-retaining eyelid speculum was placed in the eye.
We used calipers to measure and mark a location 2-3 mm be-
hind the limbus. We used forceps to stabilize the eye and con-
ducted the intravitreal injection with a 30-gauge needle. The
needle was visualized in the pupil and the drug or placebo
was injected into the midvitreous. We withdrew the needle
and instilled erythromid ointment in the fornices.
General ophthalmologic examination:  Ophthalmologic
examinations were performed before laser and followed the
scheduled examination time during the entire study period.
The fundus, anterior segment, and intraocular pressure (IOP)
were examined by indirect ophthalmoscopy, slit-lamp micros-
copy, and Tono-Pen tonometer in both eyes. The animals were
lightly sedated with ketamine hydrochloride before this pro-
cedure, and a few drops of 0.5% tropicamide and 0.4%
oxybuprocaine hydrochloride (Benoxil.RTM. 0.4% solution;
Santen Pharmaceutical) were instilled into each eye to facili-
tate the examination.
Multifocal electroretinogram analysis:  Multifocal elec-
troretinograms (mf-ERGs) were obtained before laser treat-
ment and 20 days after the infliction of the laser injury. After
the intravitreal injection of KH902, the same procedure was
applied on days 14 and 28. Mf-ERGs were recorded by a
multifocal electroretinograph diagnostic system (Roland Con-
sult Elektrophysiologische Diagnostik Systeme, Retiscan
multifocal ERG Version 3.2, Brandenburg, Germany) with
what is often referred to as the “standard” stimulus paradigm.
The “standard” visual stimuli are comprised of an array of 61
hexagonal elements displayed on a 21-inch monochrome cath-
ode ray tube at a 75 Hz frame rate. Approximately 30 min
before recording, pupils of each animal were dilated to about
6 mm and sedated with intravenous 2.5% soluble pentobarbi-
tone (1 ml/kg). A mydriatic was instilled in each eye approxi-
mately 10-15 min before the mf-ERG procedure and the ani-
mal was placed in a prone position. An intravenous 1 mg/kg
2.5% soluble pentobarbitone was given to maintain sedation.
Mf-ERG probes were placed subcutaneously beneath each eye
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38and another on top of the head posterior to the brow. Lubri-
cant (carboxymethylcellulose) was applied to each lens, and
contact lenses were placed on each eye. The mf-ERG tests
were repeated at least five times. After completion of the test,
tobramycin drops was placed in each eye.
Optical coherence tomography examination:  Under se-
dation, the animals were fixed to keep eye open and maintain
the position of the head. An OCT scan was applied with Stra-
tus OCTTM model 3000 (Carl Zeiss Medited Inc., Dublin,
CA). When fixed on the macular fovea by observation on the
monitor screen, the fast macular scan procedure was applied
to check each eye of the monkeys before the laser injury and
20 days after the injury. On days 14 and 28 after intravitreal
injection, the same OCT examination was applied again. The
analysis was kept the same by choosing the equal scan angle.
Color photography and fluorescein fundus angiography:
Color photography and fluorescein fundus angiography (FFA)
were performed before laser treatment and 20 days after laser
treatment. After intravitreal injection of the KH902, color pho-
tography and FFA were performed on days 14 and 28. The
animals were sedated with intravenous 2.5% soluble pento-
barbitone (1 ml/kg). Eyelids were fixed to keep the eye open.
Each animal was placed on an ophthalmology restraint stand
to maintain the position of the head during photography. Pho-
tographs were taken by a fundus camera (FF450 plus IRu
Retina Camera, Software Visupac version 3.5, Carl Zeiss
Meditec AG, Jena, Germany). Before the administration of
fluorescein dye, color photographs were taken first. Fluores-
cein dye (20% fluorescein sodium; 0.05 ml/kg) was then in-
jected via a vein of the lower extremity. Photographs were
taken at several time points after the dye injection including
the arterial phase, early arteriovenous phase, and several late
arteriovenous phases to monitor leakage of fluorescein asso-
ciated with CNV lesions. Color fundus photography and fluo-
rescein angiography were used to detect and measure the ex-
tent and evidence of leakage of CNV. These were performed
in a masked fashion by two of the authors (Junjun Zhang and
Mi Yan, Department of Ophthalmology, West China Hospital,
Sichuan University, Chengdu, China). Angiographically, the
burn is hypofluorescent early. If CNV is present,
hyperfluorescence develops around the burn, which progresses
to late diffuse leakage with dye pooling in the serous detach-
ment surrounding the burn area. The basis for this determina-
tion was graded by the degree of the leakage on a standard-
ized scale of 1-4. Grading scores were defined as the follow-
ings: 1, no hyperfluorescence; 2, hyperfluorescence without
leakage; 3, early hyperfluorescence and late mild leakage; and
4, early hyperfluorescence and late severe dye leakage beyond
the borders of the burn area. A grade of 4 was assigned to the
clinically significant fluorescence leakage of the classic ex-
perimental CNV. The area of the late grade 4 CNV lesion leak-
age was measured with software (Software Visupac version
3.5; Zeiss Corporation) in a masked fashion by two of the
authors (Junjun Zhang and Mi Yan, Department of Ophthal-
mology, West China Hospital, Sichuan University). Data were
analyzed by SPSS 13.0.
Histopathologic and immunohistochemistry analysis:
Animals were killed with intravenous veterinary pentobarbitol-
based euthanasia solution (Vortech Pharmaceuticals, Dearborn,
MI). The globes were carefully removed from each animal
and dissected clean of orbital tissue. The globes were rinsed
in saline and placed in modified fixative consisting of 1.5%
glutaraldehyde and 2.5% formaldehyde in 0.1 M phosphate
buffer, 7.4 pH. Four hours later, we opened a 5 mm diameter
“window” near the limbus wall of globes. Another “window”
opposite to the first one were made after one night. The globes
were then placed in a modified fixative for 24-48 h. The ante-
rior segment was dissected and discarded. The posterior pole
was changed to a buffer (0.1 M phosphate) until processed for
serial section. A 3 µm section that contained lesions of inter-
est was prepared to hematoxylin and eosin-staining and CD31
and CD105 immunohistochemistry staining for analysis.
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Figure 1. Binding affinity of KH902 for vascular endothelial growth
factor.  Affinities of indicated KH902 for VEGF was determined by
using a binding assay that measures free VEGF (ordinate) after incu-
bation of 10 pM of human VEGF165 with varying concentrations of
KH902 (abscissa).
Figure 2. The effect of KH902 on vascular endothelial growth fac-
tor-induced human umbilical vein endothelial cell proliferation.
KH902 effectively inhibits VEGF-induced HUVEC proliferation. The
medium containing 0.2 nM VEGF increased cell growth of HUVEC.
However, KH902 presents the inhibition on cell growth at a concen-
tration of 10 nM. It can also almost completely block the VEGF-
induced effect at 41 nM.
39The paraffin sections were soaked in dimethyl benzene
and gradient alcohol for deparaffinage then digested with 0.1%
trypsin to repair the antigen (for 0.5 h at 37 °C). The sections
were incubated with CD31 monoclonal antibody (Rabbit an-
tibody, dilution 1:300) and CD105 monoclonal antibody
(Mouse antibody, dilution 1:100,) for 2 h at 37 °C. Normal
rabbit serum (dilution 1:100 in PBS) was used as a negative
control. Washing was performed with PBS, and sections were
incubated with the secondary anti-mouse antibody conjugated
with FITC (dilution 1:50; Cappel, Durham, NC) and the anti-
rabbit antibody conjugated with tetramethyl rhodamine
isothiocyanate (TRITC; dilution 1:200; Cappel). After incu-
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Figure 3. Mean area changes of grade 4 spots on day 20 after laser,
day 14 and day 28 after intravitreal injection in control, 100 µg, 300
µg, and 500 µg KH902-treated groups.  CNV spots were graded on a
scale of 1-4 20 days after laser and on days 14 and 28 after intravitreal
injection. The bigger area of grade 4 spots represented greater CNV
leakage. The area of neovascularization was significantly less on days
14 and 28 than on day 20 after laser in the 300 µg and 500 µg KH902-
treated eyes. Furthermore, the area was significant lower in the 300
µg and 500 µg KH902-treated eyes than in the control and 100 µg
KH902-treated eyes (ANOVA, p<0.001). Grading scores were de-
fined as follows: 1, no hyperfluorescence; 2, hyperfluorescence with-
out leakage; 3, early hyperfluorescence and late mild leakage; 4, early
hyperfluorescence and late severely dye leakage which transit and
beyond the borders of the laser burn lesion.
Figure 4. Color photography and angiography of an eye that received injection of vehicle taken on day 20 after laser and on days 14 and 28
after intravitreal injection.  Color photo and fluorescein angiography of experimental model of choroidal neovascularization treated with
injection of vehicle is shown. Note the gray-white change of lesions, local retina edema on color image and the large confluent bridging lesions
and extensive late leakage on angiography image in left eye. There were no changes among three time points: day 20 after laser, day 14 and 28
after intravitreal injection.
40bation for 2 h at 37 °C, washing was performed with PBS.
Sections were mounted with DAPI mounting medium and
observed with a fluorescence microscope (Nikon TE2000-U;
Nikon Co, Ltd., Tokyo, Japan).
Statistical analysis:  Data are presented as mean±SD and
analyzed by SPSS 13.0 software. The difference among the
means of the groups is determined with ANOVA. When a sig-
nificant difference is determined, the Dunnett post hoc analy-
sis is used. p<0.05 was considered significant.
RESULTS
KH902 high binding affinity to vascular endothelial growth
factor:  The amount of unbound VEGF165 was measured,
revealing that the IC50 of KH902 was between 7-15 pM. We
repeated the binding assay several times with the results shown
in Figure 1. As shown in the results, KH902 has a high affin-
ity with VEGF, and the mean IC50 was 10 pM.
KH902 blocks vascular endothelial growth factor-induced
human umbilical vein endothelial cell proliferation:  The
growth of endothelial cells are induced by a lot of factors in-
cluding VEGF. To determine whether KH902 binding of VEGF
could potently and effectively block the ability of VEGF to
enhance endothelial cells proliferation, VEGF and KH902 were
added to HUVECs and the effect on proliferation was exam-
ined. The results as shown in Figure 2 demonstrate that KH902
at 41 nM can completely block VEGF-induced cell prolifera-
tion, and KH902 at 10.7 nM can block 82.6% of cell growth
(Figure 2).
KH902 inhibits the growth and leakage of experimental
monkey choroidal neovascularization:  To determine the over-
all effect of a single injection of KH902 on the inhibition of
laser-induced CNV, the areas of CNV for all time points were
combined and averaged. This analysis demonstrated that 300
µg and 500 µg of KH902 inhibited growth of the neovascular
area compared to findings in the control and animals treated
with 100 µg KH902 (p<0.001 for 300 µg and 500 µg when
compared with control and 100 µg). To assess the efficacy of
KH902 over time, we measured growth of the CNV area be-
yond the laser spot on day 20 after laser injury and on days 14
and 28 after intravitreal injection. The results showed that on
days 14 and 28, the area of neovascularization was signifi-
cantly lower in the 300 µg and 500 µg KH902-treated eyes
compared to the control and 100 µg KH902-treated eyes
(p<0.001; Figure 3). Thus, with one injection of KH902,
neovascular growth remained inhibited throughout the 28-day
follow-up period.
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Figure 5. Color photography and angiography of an eye that received injection of 100 µg KH902 taken on day 20 after laser, days 14 and 28
after intravitreal injection.  Color photo and fluorescein angiography of experimental model of choroidal neovascularization treated with
injection of 100 µg KH902 is shown. Note the gray-white appearance of lesions and local retina edema on color image. The large confluent
bridging lesions and extensive late leakage were shown on angiography image of right eye on day 20 after laser. On days 14 and 28 after
intravitreal injection, laser lesion and late leakage decreases a little but still kept extensive late leakage.
41In addition to size, a single injection of KH902 was ca-
pable of decreasing the leakage. Both early and late fluores-
cein angiograms taken on days 14 and 28 demonstrate that
leakage was inhibited in KH902-treated eyes. The eye that
received an injection of the vehicle demonstrated a large
confluent bridging lesion and extensive late leakage (Figure 4
and Figure 5). In contrast, an eye treated with 300 µg of KH902
or 500 µg of KH902 demonstrated not only an imperceptible
increase in size of the laser lesion but also no late leakage of
any of the laser spots (Figure 6 and Figure 7).
Through analysis of angiograms at each dose level, the
proportion of spots that had clinically significant leakage as
defined by a grade of 4 could be calculated for each time point
(Table 1). On day 20 after laser burn, the control eyes had as
much as 68.75%±44.19% of spots with active leakage as com-
pared to 53.13%±25.77%, 53.13%±25.77%, and
71.88%±27.72% of spots in eyes injected with 100 µg, 300
µg, and 500 µg, respectively, of KH902. On day 14 after
intravitreal injection, the percentage of spots with leakage
decreased to 12.5%±25% and 6.25%±12.5% in 300 µg and
500 µg KH902-treated eyes, respectively, as compared to
62.5%±35.36% and 12.5%±25% in control and 100 µg
KH902-treated eyes. The difference between eyes treated with
300 µg or 500 µg KH902 and eyes treated with 100 µg KH902
or buffer are still significant (p<0.05). On day 28 after
intravitreal injection, the proportion of grade 4 spots in 300
µg and 500 µg KH902-treated eyes was 3.13%±6.25%. It was
markedly decreased after intravitreal injection compared with
that on day 20 after laser burn (p<0.001). In control and 100
µg KH902-treated eyes, the proportion of grade 4 spots were
the same as it was on day 14.
There was no apparent complication related to intravitreal
injection of KH902. Throughout the experiment, no inflam-
mation, cataract formation, retinal detachment, or vitreous
hemorrhage was noted in any of the animals. The intraocular
pressure results showed no significant change between the
baseline and the after injection time point in any of the treated
or control animals.
To confirm that angiographically measured and graded
lesions represented CNV, angiograms were correlated to OCT
and histopathologic findings. OCT image and histopathology
confirmed that angiographically measured CNV that stained
or leaked represented subretinal neovascularization and that
the extent of angiographically measured lesions corresponded
to the histological edge of the lesions.
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Figure 6. Color photography and angiography of an eye that received injection of 300 µg KH902 taken on day 20 after laser and on days 14 and
28 after intravitreal injection.  Color photo and fluorescein angiography of experimental model of choroidal neovascularization treated with
injection of 300 µg KH902 is shown. Note the gray-white appearance of lesions and local retina edema in the color image. The large confluent
bridging lesions and extensive late leakage were demonstrated on angiography image in left eye on days 20 after laser. On day 14 after
intravitreal injection, local edema and late leakage of lesions decreased. Furthermore, on day 28 after intravitreal injection, there was no
evidence of retina edema and late leakage.
42On day 20 after laser burn, the high reflect light echogenic
masses similar to human pathologic CNV were detected in all
animals eyes. Neuroretina edema and abnormal macular fovea
due to the CNV were demonstrated by OCT scan image. In
the control and 100 µg KH902-treated eyes, there were no
obvious changes on days 14 and 28 after intravitreal injection
(Figure 8A-D). However, a marked change was detected in
300 µg and 500 µg KH902-treated eyes on days 14 and 28
after intravitreal injection. The light echogenic mass disap-
peared on the OCT scan image. The light echogenic band of
retinal pigment epithelial became regular and continuous.
Edema of the retina faded away and the shape of macula fovea
centralis recovered (Figure 8E-H).
Histology analysis results indicated rupture of Bruch’s
membrane and subretinal hyperblastosis in the control group
eye section and in the 100 µg KH902-treated eye
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Figure 7. Color photography and angiography of an eye that received injection of 500 µg KH902 taken on day 20 after laser and days 14 and
28 after intravitreal injection.  Color photo and fluorescein angiography of the experimental model of choroidal neovascularization treated
with injection of 500 µg KH902 is shown. Note the gray-white appearance of lesions and local retina edema on color image. The large
confluent bridging lesions and extensive late leakage were demonstrated on angiography image in left eye on days 20 after laser.
TABLE 1. COMPARISON OF THE PROPORTION OF GRADE 4 SPOTS IN FLUORESCENCE FUNDUS ANGIOGRAPHY BETWEEN DAY 21 AFTER LASER BURN AND
DAYS 14 AND 28 AFTER INTRAVITREAL INJECTION OF KH902
The asterisk indicates that it is compared with the predose and the difference is significant using one way ANOVA analysis. When the
difference among three groups is significant, post hoc dunnett was used to analyze the difference between the adminstration group and the
predose group.
43section(Figure 9A,B). The proliferation-associated endothe-
lial cells stained with CD31 and CD105 (Figure 10A,B), reti-
nal pigment epithelial cells, macrophagus, and fibrocytes were
seen under microscopy (Figure 9A,B). The absence of an outer
nuclear layer and retinal edema were obvious. In the 300 µg
and 500 µg KH902-treated eye sections, there were distinct
retinal structure and no edema. The absent outer nuclear layer
and a few fibrocytes were observed (Figure 9C,D), but there
were no proliferation-associated endothelial cells stained with
CD31 and CD105 (Figure 10C,D).
KH902 improved the local multifocal electroretinogram
of the macula involved by CNV in the monkey:  Local mf-
ERG measurement allows for mapping of retinal function, and
the location of dysfunction in the retina can be indicative of
its future potential impact on vision. On day 20 after laser
burn, the three dimensional map of mf-ERG demonstrated that
the peak of the macular and the amplitudes of the retina corre-
sponding to those involved in CNV cut down markedly. Local
dysfunction in the macular retina could be presented clearly.
In the control eyes, the abnormality presented no change on
days 14 and 28 after intravitreal injection. However, in treated
eyes on day 20 after laser, the amplitudes increased and the
function of locally involved retina improved. Especially on
day 28, the peak of the macular recovered and the map of the
macular retina improved in those that received 300 µg and
500 µg KH902 (Figure 11).
DISCUSSION
 The process of angiogenesis is multi-factorial and highly com-
plex, but vascular endothelial growth factor (VEGF) is con-
sidered critical both in physiologic and in pathological angio-
genesis [13] such as in AMD [14,15]. Binding of VEGF-A to
its receptors leads to endothelial cell proliferation and
neovascularization as well as vascular leakage, all of which
are thought to contribute to the progression of the neovascular
(wet) form of age-related macular degeneration, one of the
leading causes of legal blindness. There are also a consider-
able number of publications showing that by antagonizing
VEGF, angiogenesis and vascular permeability can be pre-
vented [11,12,16-18].
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Figure 8. Optical coherence to-
mography scan image on day
20 after laser burn and day 28
after intravitreal injection in
four groups.  The high reflect
light echogenic mass (white
arrowheads) were detected in
the eyes on day 20 after laser
burn and in the eye of control
on day 28 after intravitreal in-
jection. The light echogenic
mass disappeared after injec-
tion compared with that before
injection. The light echogenic
band of retinal pigment epithe-
lial became regular and con-
tinuous. Edema of the retina
faded away and the shape of
the macula fovea centralis re-
covered.
44There are currently two inhibitors of VEGF, Pegaptanib
and Ranibizumab, which are approved by the FDA for the
treatment of exudative AMD and under commercial develop-
ment. Both of them could inhibit the ocular neovascularization
efficiently, but frequent administration was required to main-
tain the therapeutic level of VEGF inhibition. Furthermore,
frequent administration, which requires patients to be injected
every four to six weeks, has been performed in clinical trials
[11,12]. These limitations provide an opportunity to develop
better VEGF inhibitors that can potentially be administered
less frequently and act more potently.
VEGF-Trap, a unique VEGF blocker, is a fusion protein
of key domains from VEGF receptor 1 and 2 with human IgG
Fc. It has a high affinity with VEGF and blocks all VEGF-A
isoforms and placental growth factors. It can also penetrate
all layers of the retina. The interim results of the Phase II clini-
cal trial show that the mean change from the baseline in visual
acuity demonstrated statistically significant improvement (all
groups combined increase 5.9 letters, p<0.0001), and monthly
and quarterly dosing did not result in substantially different
results at eight weeks [19].
In the current study, we designed a molecule KH902, simi-
lar to VEGF-Trap. It combines ligand binding elements taken
from the extracellular domain 2 of VEGF receptors 1(Flt-1)
and extracellular domain 3 of VEGF receptors 2 (KDR) fused
to the Fc portion of human IgG1. The molecule still contains a
extracellular domain 4 of VEGF receptors 2(KDRd4), which
can improve the three-dimensional structure and increase the
dimerization efficiently [20,21] so that KH902 presents high
affinity with VEGF. By human VEGF ELISA assay, the IC50
of KH902 was 7-15 pM and the mean IC50 was 10 pM. Com-
pared with avastin, an off-label anti-VEGF drug which was
administrated to treat wet-AMD in fashion, the affinity of
KH902 was 50 fold times more than that of avastin and equally
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Figure 9. Ocular histology (hematoxylin-eosin stain) of all four groups at the endpoint of the experiment.  The subretinal hyperblastosis (black
arrowheads) in the control group and 100 µg KH902-treated group is shown. The outer nuclear layer was absent and retinal edema was
obviously exhibited (A,B). In the 300 µg and 500 µg KH902-treated eyes, there were distinct retinal structures and no edema. The absent outer
nuclear layer and a few fibrocytes were observed (C,D).
45more efficient in inhibiting the proliferation of human umbili-
cal vein endothelial cells induced by VEGF. Meanwhile,
KDRd4 degrades the isoelectric point (PI) of KH902, which
maintain the soluble state of the active proteins and may thus
prolongs the clearance time of KH902 in the vitreous. We will
confirm the hypothesis in later pharmacokinetic experiment.
Furthermore, we sought to demonstrate the efficacy of
KH902 in a clinically relevant model of CNV. What we have
shown in this study is that a single intravitreal injection of
KH902 targeting VEGF can prevent growth of CNV and at-
tenuate vascular leakage of CNV for at least four weeks. A
single injection of our high dose KH902 suppressed leakage
throughout the follow-up period, indicating that the duration
of action on vascular permeability with one injection of KH902
is at least four weeks, especially at our higher dose. At the
dose levels used in this study, no evidence of inflammation or
toxicity was noted. Formal animal toxicity studies are neces-
sary to determine the highest acceptable dose level that can be
delivered to the eye. This study illustrates the potency of
KH902 as a therapeutic class of molecule. As a therapeutic
agent, KH902 is potent, highly soluble, shows no toxicity, and
appears to have an effective suppression action on CNV.
The stimulus for neovascularization in laser-induced le-
sion models obviously differs from that in AMD because la-
ser models invoke a traumatic repair process that may mimic
traumatic CNV development better than AMD-related CNV.
However, there are also substantial similarities between AMD-
related CNV and laser-induced CNV. Investigators using a pri-
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Figure 10. Merged images of immunohistochemistry.  Immunohistochemistry analysis of proliferation-associated endothelial cells (stained by
CD31/CD105 and DAPI) in all four groups at the endpoint of the experiment is shown. The proliferation-associated endothelial cells of
choroidal neovascularization were stained with CD31 and CD105 (yellow arrowheads) like choroidal vessel endothelial cells in the control
eye and 100 µg KH902-treated eye (A,B) whereas no positive stained proliferation-associated endothelial cells were found in 300 µg and 500
µg KH902-treated eye (C,D).
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Figure 11. Local multifocal electroretinogram measurements on day 20 after laser and on day 28 after intravitreal injection.  On day 20 after
laser burn, the peak of the macular and the amplitudes of the retina that corresponded to those involved in CNV was markedly cut down. On
day 28 after injection, the amplitudes increased and the function of locally involved retina improved compared to the results on day 20 after
laser burn in the KH902-treated eyes, especially in the 300 µg and 500 µg KH902-treated one. But, there was no marked change in the control
eye.
47mate laser model have postulated that macrophages, involved
in the initial response to Bruch’s membrane injury after laser
exposure, secrete angiogenic growth factors. These growth
factors are probably mechanistically relevant to human CNV
formation as surgically excised and postmortem CNV and RPE
cells in human tissues have shown immunoreactivity for these
same growth factors.
In our study, we used the mf-ERG examination to dem-
onstrate locally involved macular function variation during
the experiment. The results of mf-ERG demonstrated the im-
provement was greater in 300 µg and 500 µg KH902-treated
eyes than in the 100 µg KH902-treated eyes and eyes of the
control group. These results imply that the central vision of
monkey eyes impaired by laser-induced CNV obtained im-
provement after intravitreal injection of KH902.
In summary, KH902, the molecule with a high affinity
binding for VEGF, effectively inhibits the proliferation of hu-
man umbilical endothelial cells induced by VEGF in vitro. A
single intravitreal administration of KH902 successfully pre-
vented lesion growth and leakage of choroidal neovascular in
a nonhuman primate model. In addition, this preclinical proof
of principle provides a guideline for dosing in humans and
provides strong support for advancing this molecule into clini-
cal trials for the treatment of wet age-related macular degen-
eration.
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